ArticleJTO clinical and research reports2024

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations.

Yuki Takeyasu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.